A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
High urgency

Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications

Detected July 16, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA is withdrawing approval of 34 NDAs from Endo Operations Limited and other applicants, removing these drugs from the market. This affects manufacturers, suppliers, and distributors of these products.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) involved with the 34 withdrawn NDAs. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (July 6, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA has withdrawn approval of 34 NDAs, meaning these drugs are no longer approved and cannot be legally marketed or distributed in the U.S.

Who it affects

Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) involved with the 34 withdrawn NDAs.

What you must do

Cease distribution and marketing of the affected drugs immediately. Remove them from inventory and notify supply chain partners.

Deadline

Immediately upon publication (July 6, 2026).

Source: https://www.federalregister.gov/documents/2026/07/06/2026-13616/endo-operations-limited-et-al-withdrawal-of-approval-of-34-new-drug-applications

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)